Rep. Brett Guthrie

Maddy summaryThe ANTE Act gives the U.S. International Trade Commission (USITC) new authority to investigate whether companies owned by non-market economy countries (like China or Russia, as defined by U.S. trade agencies) are using third countries (e.g., Vietnam or Mexico) to avoid U.S. tariffs on their goods. If the USITC finds evidence of tariff evasion - such as production in a third country to bypass tariffs on goods from a non-market economy - it can recommend trade remedies to the President or Congress. These remedies could include targeted tariffs on the third-country investment or broader import restrictions, requiring Congress to act within 60 days via a joint resolution. The policy would last 3-8 years, with automatic review before expiration to assess if the evasion threat persists. This directly affects companies in non-market economies seeking to circumvent U.S. trade penalties through third-country operations.

Maddy summaryThis bill prohibits the import of eight specific minerals (including copper, nickel, palladium, and platinum) from Russia or Russian entities starting 90 days after enactment. It directly affects U.S. importers and businesses relying on these Russian-sourced minerals. The ban ends one year after the President certifies Russia has ceased hostilities against Ukraine, but resumes immediately if Russia restarts military action, with no presidential waivers allowed. The law remains in effect until a new certification confirms Russia's cessation of hostilities.

Maddy summaryThe Patient Access Act of 2024 allows drug manufacturers to cover certain travel, lodging, and meal expenses for patients prescribed specialty drugs who live more than 1 hour driving distance (or 50 miles) from a treatment facility and have income below the median for their area. It permits manufacturers to pay for transportation, lodging near the facility, and meals during treatment periods, but only if patients aren’t already receiving these services for free from the facility and manufacturers don’t advertise the program before a prescription is issued. The bill also requires manufacturers to certify they won’t shift costs to Medicare or Medicaid and mandates a GAO study to track impacts on access, costs, and disparities for these patients. This applies specifically to patients needing transformative therapies like rare disease treatments, with the program starting January 1, 2025.

Maddy summaryThis bill creates temporary waivers for skilled nursing facilities and nursing facilities in areas with severe nurse aide shortages. It allows states to waive specific training and certification requirements for facilities located in designated shortage areas that haven't had recent quality-of-care deficiencies. Key provisions include extending the required nurse aide training period from 4 to 12 months, counting on-the-job hours toward training requirements, and offering flexibility in competency evaluations when state options are limited. The waivers apply to both Medicare and Medicaid-certified facilities meeting the defined shortage and quality criteria.

Maddy summaryHR 7836 would permanently remove import duties (taxes) on basketballs entering the United States. This bill directly affects businesses that import basketballs by eliminating the 30% tax they previously paid. The key mechanism is adding a new tariff classification (9506.62.70) to the US import rules, designating basketballs as duty-free. The change takes effect 15 days after the bill becomes law.

Maddy summaryThis bill changes the negotiation period for small-molecule drugs under the federal Drug Price Negotiation Program from 7 years to 11 years, matching the existing 11-year period for biologic drugs. It directly affects drug manufacturers participating in the program by extending the timeframe for price negotiations with the government. The amendment applies to all small-molecule drugs covered under the program, creating a uniform negotiation timeline for both drug types. The change takes effect as if included in the Inflation Reduction Act of 2022.

Maddy summaryThis bill amends the Social Security Act to require states to establish child support obligations for the biological father of an unborn child when the mother requests it. Key provisions include allowing support to begin from the month of conception (as determined by a physician), permitting retroactive payments even if paternity is established after birth, and requiring court determination of payment amounts based on the mother's and child's best interests. It prohibits forced paternity testing for unborn children if it risks harm and explicitly bans any experimental programs from modifying these provisions. The bill directly affects mothers of unborn children and biological fathers, expanding child support enforcement to cover pregnancy.

Maddy summaryThis bill requires Medicare to improve transparency in its national coverage decision process for medical treatments and devices. It mandates that Medicare (through the Secretary of Health and Human Services) must determine within 30 days if a submission is a complete request for a coverage decision, and if not, provide specific feedback on missing information. Complete requests must be posted publicly on a government website within two business days, and annual reports must include the time between submission and the point when the request was deemed complete. This directly affects healthcare providers, pharmaceutical companies, and medical device manufacturers seeking Medicare coverage for new treatments.

Maddy summaryThis bill prohibits Medicare from paying for certain custom-fitted or custom-fabricated orthotic and prosthetic devices delivered via "drop shipment" (direct shipping without in-person training from a qualified provider). It directly affects Medicare beneficiaries who need these devices, ensuring they receive necessary in-person fitting and training. The bill also expands which healthcare professionals (including physical therapists, occupational therapists, orthotists, and prosthetists) can prescribe these devices and updates definitions to clarify terms like "orthoses" and "prostheses." Final regulations implementing these changes must be issued within one year of the bill's enactment.

Maddy summaryHR 4073, the Duty Drawback Clarification Act, clarifies U.S. tariff classifications for imported whiskies by creating specific subheadings in the Harmonized Tariff Schedule. It replaces a single tariff line with eight new subheadings that categorize whiskies by type (Irish/Scotch, Bourbon, Rye, or "Other") and container size (under or over 4 liters), each with a uniform duty rate of $2.04 per liter. This change directly affects whiskey importers and manufacturers who must now classify products using these new codes when entering goods into U.S. commerce. The bill streamlines duty calculation and drawback claims (refunds of duties on imported goods later exported) by standardizing the tariff structure for whiskey categories.